Investigating how pancreatic cancer responds to specific immunotherapies and genetic factors
Homologous recombination deficiency and beyond in pancreatic cancer: evaluating the regulators of response to pembrolizumab and olaparib (POLAR) from the immune and genomic perspectives
This study is looking at a type of pancreatic cancer to see if certain patients with specific genetic traits can benefit more from a combination of immune treatments and other therapies, with the goal of improving how well these treatments work for them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10908416 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a type of cancer known for its resistance to immunotherapy. The study aims to identify patient subgroups that may respond better to treatments combining immune checkpoint inhibitors with poly-ADP ribose polymerase inhibitors (PARPi). By analyzing genetic factors and the tumor microenvironment, researchers hope to enhance treatment efficacy and improve patient outcomes. Patients with specific genetic mutations may be particularly studied to understand their responses to these therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with pancreatic ductal adenocarcinoma, especially those with specific genetic mutations like BRCA or PALB2.
Not a fit: Patients with non-pancreatic cancers or those without the relevant genetic mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Previous studies have shown promising results with similar approaches in enhancing the effectiveness of immunotherapy in cancer treatment.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: O'reilly, Eileen Mary — Sloan-Kettering Inst Can Research
- Study coordinator: O'reilly, Eileen Mary
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.